Graphical user interface for a display screen or portion thereof

- BioNTech SE
Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

The patent or application file contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 is an image of a graphical user interface for a display screen or portion thereof showing our new design, according to an embodiment; and,

FIG. 2 is an image of a graphical user interface for a display screen or portion thereof showing our new design, according to a second embodiment.

The outer broken line perimeter shows the display screen or portion thereof and forms no part of the claimed design. The remaining broken lines show parts of the graphical user interface that form no part of the claimed design.

Claims

The ornamental design for a graphical user interface for a display screen or portion thereof as shown and described.

Referenced Cited
U.S. Patent Documents
7376739 May 20, 2008 Ramaswamy et al.
8163146 April 24, 2012 Forrow
D703690 April 29, 2014 MacCubbin
D727942 April 28, 2015 Angelides
D752085 March 22, 2016 Staiano et al.
D756373 May 17, 2016 Raskin
D756391 May 17, 2016 Kouvas
D775635 January 3, 2017 Raji
D780778 March 7, 2017 Wiggins et al.
D786277 May 9, 2017 Kim
D786896 May 16, 2017 Kim
D790565 June 27, 2017 Phelps
D799509 October 10, 2017 Wiggins et al.
D809550 February 6, 2018 Bray
D814494 April 3, 2018 Stiansen
D818474 May 22, 2018 Kato et al.
D820290 June 12, 2018 Laing
D820871 June 19, 2018 Inman et al.
D824923 August 7, 2018 Anderson et al.
D841023 February 19, 2019 Millett
D864222 October 22, 2019 Paulina
D890197 July 14, 2020 Cornet et al.
D890199 July 14, 2020 Kumar
D895648 September 8, 2020 Dye
D899454 October 20, 2020 Rondoni
D911375 February 23, 2021 Zhao et al.
D915427 April 6, 2021 Cui et al.
D916739 April 20, 2021 Saltik
D916758 April 20, 2021 Dye
D917517 April 27, 2021 Dye
11011253 May 18, 2021 Hie et al.
D921653 June 8, 2021 Rowlett Leslie
D926810 August 3, 2021 Murphy
D938982 December 21, 2021 Cui
D949885 April 26, 2022 Bieter et al.
D955419 June 21, 2022 Drapeau
D963676 September 13, 2022 Bahatyrevich
D968419 November 1, 2022 Hansen et al.
11526261 December 13, 2022 Leach
D976941 January 31, 2023 Butter et al.
D981432 March 21, 2023 Bahatyrevich
D988348 June 6, 2023 Watanabe
D994683 August 8, 2023 Felton
D999229 September 19, 2023 Bieter et al.
D1004603 November 14, 2023 Song et al.
D1008293 December 19, 2023 Baez
11875163 January 16, 2024 Sharma
D1013705 February 6, 2024 Bahatyrevich
D1035695 July 16, 2024 Chang
D1038961 August 13, 2024 Felton
D1046882 October 15, 2024 Furuiye
D1060409 February 4, 2025 Kastner et al.
D1071954 April 22, 2025 Felton
D1074724 May 13, 2025 Bost et al.
D1080643 June 24, 2025 Dobson
D1091599 September 2, 2025 Caster
D1098136 October 14, 2025 Baghdadi et al.
D1099124 October 21, 2025 Chiu
D1113940 February 17, 2026 Simcock
D1119917 March 24, 2026 Ough
D1122283 April 14, 2026 Chiu
20040153189 August 5, 2004 Emerson
20080058625 March 6, 2008 McGarraugh
20090089352 April 2, 2009 Davis et al.
20110205231 August 25, 2011 Hartley et al.
20130097177 April 18, 2013 Fan
20140088392 March 27, 2014 Bernstein
20140365952 December 11, 2014 Honeyman
20150170288 June 18, 2015 Harton et al.
20170168701 June 15, 2017 Mackinlay et al.
20210124478 April 29, 2021 Reese et al.
20210228707 July 29, 2021 Metkar et al.
20210303558 September 30, 2021 Setlur et al.
20220013194 January 13, 2022 Hie et al.
20220108507 April 7, 2022 Degtyar et al.
20220125480 April 28, 2022 Rao
20230039827 February 9, 2023 Wani et al.
20230310587 October 5, 2023 Niesen et al.
20240000921 January 4, 2024 Muik
20240176469 May 30, 2024 Zeng et al.
20240321387 September 26, 2024 Muik et al.
20240339174 October 10, 2024 Muik et al.
20240401465 December 5, 2024 Sureka
20250263691 August 21, 2025 Haas
20250391262 December 25, 2025 Ronen
Foreign Patent Documents
113470745 October 2021 CN
202230187677.6 June 2022 CN
005506441-0001 February 2022 EM
2021008246 January 2021 JP
2021013408 March 2022 JP
WO-2007/036366 April 2007 WO
WO-2008/157688 December 2008 WO
WO-2011/015347 February 2011 WO
WO-2013/143683 October 2013 WO
WO-2016/005324 January 2016 WO
WO-2016/046060 March 2016 WO
WO-2017/053297 March 2017 WO
WO-2017/060314 April 2017 WO
WO-2017/075531 May 2017 WO
WO-2018/081480 May 2018 WO
WO-2019/077053 April 2019 WO
WO-2021/154763 August 2021 WO
WO-2021/159040 August 2021 WO
WO-2021/159130 August 2021 WO
WO-2021/213924 October 2021 WO
WO-2021/213945 October 2021 WO
WO-2021/214204 October 2021 WO
WO-2021/222304 November 2021 WO
WO-2022/011231 January 2022 WO
WO-2022/235847 November 2022 WO
WO-2022/235853 November 2022 WO
WO-2022/235853 January 2023 WO
WO-2023/177577 September 2023 WO
WO-2023/193025 October 2023 WO
WO-2024/206431 October 2024 WO
WO-2024/206447 October 2024 WO
Other references
  • “Graphia user interface displaying a correlation graph” Sep. 2020, ResearchGate, site visited Dec. 31, 2025: https://www.researchgate.net/figure/Graphia-user-interface-displaying-a-correlation-graph-A-Graph-display-area-showing_fig1_344152721 (Year: 2020).
  • “STAGEs_ A web-based tool that integrates data visualization and pathway enrichment analysis for gene expression studies” May 2, 2023, Scientific Reports, site visited Dec. 31, 2025: https://www.nature.com/articles/s41598-023-34163-2 (Year: 2023).
  • “Illustrations of visualization outputs from 3D RNA-seq” May 2019, ResearchGate, site visited Dec. 31, 2025: https://www.researchgate.net/figure/Ilustrations-of-visualization-outputs-from-3D-RNA-seq-A-Summary-figure-of-expressed_fig1_333533929 (Year: 2019).
  • “Graphs and Charts UI Pack” Oct. 2, 2014, Behance, site visited Dec. 31, 2025: https://www.behance.net/gallery/20218015/Graphs-and-Charts-UI-Pack (Year: 2014).
  • Althaus, C.L. and De Boer, R.J., Dynamics of immune escape during HIV/SIV infection, PLoS Comput Biol., 4(7):e1000103, 9 pages (2008).
  • Altschul, S. et al., Basic Local Alignment Search Tool, J. Mol. Biol., 215(3): 403-410 (1990).
  • Altschul, S. et al., Gapped Blast and PSI-Blast: a new generation of protein database search programs, Nucleic Acids Res., 25(17):3389-402 (1997).
  • Andreano, E. and Rappuoli, R., Immunodominant antibody germlines in COVID-19, J Exp Med., 218(5):e20210281, 2 pages (2021).
  • Andreano, E. et al., Extremely potent human monoclonal antibodies from COVID-19 convalescent patients, Cell, 184(7):1821-1835 (2021).
  • Author Unknown, Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, World Health Organization, 3 pages (Nov. 26, 2021).
  • Barnes, C. et al., SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies, Nature, 588(7839):682-687 (2020).
  • Baxevanis, A. et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 646 pages (1998).
  • Becht, E. et al., Dimensionality reduction for visualizing single-cell data using UMAP, Nat. Biotechnol., 37:38-44 (2018).
  • Beguir, K. et al., Early computational detection of potential high-risk SARS-CoV-2 variants, Comput Biol Med., 155:106618, 9 pages (2023).
  • Berger Rentsch, M. and Zimmer, G., A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon, PLoS One,6(10):e25858, 8 pages (2011).
  • Bojar, et al., Deep-learning resources for studying glycan mediated host microbe interactions, Cell Host and Microbe, vol. 29, Jan. 13, 2021.
  • Buchholz, U. et al., Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity, Proc Natl Acad Sci USA, 101(26):9804-9 (2004).
  • Burton, D.R. and Walker, L.M., Rational Vaccine Design in the Time of COVID-19, Cell Host Microbe., 27(5):695-698 (2020).
  • Burton, D.R et al., HIV vaccine design and the neutralizing antibody problem, Nat Immunol., 5(3):233-6 (2004).
  • Cerutti, G. et al., Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite, Cell Host Microbe., 29(5):819-833 (2021).
  • Cerutti, G. et al., Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies, Structure, 29(7):655-663 (2021).
  • Chai, N. et al., Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody, PLoS Pathogens, 29 pages (2016).
  • Chen, R. et al., Resistance of SARS-CoV-2 variants to neutralization by monclonal and serum-derived polyclonal antibodies, Nature Medicine, 27:717-726 (2021).
  • Chi, X. et al., A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2, Science, 369:650-655 (2020).
  • Cideron, G. et al., QD-RL: Efficient Mixing of Quality and Diversity in Reinforcement Learning, 16 pages (2020).
  • Corey, L. et al., SARS-CoV-2 Variants in Patients with Immunosuppression, N. Engl. J Med., 385:562-566 (2021).
  • Correia, B. et al., Proof of principle for epitope-focused vaccine design, Nature, 507(7491):201-6 (2014).
  • Corti, D. et al., Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus, Proc Natl Acad Sci USA, 112(33):10473-8 (2015).
  • Crowe, Jr., James E., Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design, Cell Host Microbe, 22(2):193-206 (2017).
  • Dejnirattisai, W. et al., The antigenic anatomy of SARS-CoV-2 receptor binding domain, Cell, 184(8):2183-2200.e22 (2021).
  • Devlin, J. et al., Bert: Pre-training of Deep Bidirectional Transformers for Language Understanding, arXiv, 16 pages (May 24, 2019).
  • Elnaggar, A. et al., ProtTrans: Toward Understanding the Language of Life Through Self-Supervised Learning, IEEE Trans Pattern Anal Mach Intell., 44(10):7112-7127 (2022).
  • Elnaggar, A. et al., ProtTrans: Towards Cracking the Language of Life's Code Through Self-Supervised Learning, IEEE Trans Pattern Analysis & Machine Intelligence, 14(8): 29 pages, 2021.
  • Fleury, D. et al., Antigen distortion allows influenza virus to escape neutralization, Nat Struct Biol., 5(2):119-23 (1998).
  • Freunde von Gisaid e.V., H5N1 Bird Flu Circulating in Dairy Cows in the United States, 2 pages (as of Jul. 6, 2024).
  • Gobeil, S. et al., Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity, Science, 373(6555):eabi6226 (2021).
  • Goulder, P. et al., Evolution and transmission of stable CTL escape mutations in HIV infection, Nature, 412(6844):334-8 (2001).
  • Greaney, A. et al., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies, Cell Host Microbe, 29(3):463-476 (2021).
  • Greaney, A. et al., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition, Cell Host Microbe, 29(1):44-57 (2021).
  • Hansen, J. et al., Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science, 369(6506):1010-1014 (2020).
  • Hatcher, E. et al., Virus Variation Resource—improved response to emergent viral outbreaks, Nucleic Acids Res., 45(D1):D482-D490 (2017).
  • Hie, B. et al., Learning the language of viral evolution and escape, Science, 371:284-288 (2021).
  • Hie, B. et al., Supplementary Material for Learning the language of viral evolution and escape, Science, 371(6526):284-288 (2021).
  • Hu, J. et al., Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies, Cell Mol Immunol., 18(4):1061-1063 (2021).
  • Ju, B. et al., Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature, 584(7819):115-119 (2020).
  • Kingma, D. and Ba, J., Adam: A Method for Stochastic Optimization, arXiv, 15 pages (Jan. 30, 2017).
  • Leslie, A. et al., HIV evolution: CTL escape mutation and reversion after transmission, Nat Med., 10(3):282-9 (2004).
  • Li, C. et al., Selection of antigenically advanced variants of seasonal influenza viruses, Nat Microbiol., 1(6):16058 (2016).
  • Liu Y. et al., Neutralizing activity of BNT162b2-elicited serum. New England Journal of Medicine 384.15 (2021): 1466-1468.
  • Liu, J. et al., BNT162b2-elicited neutralization of B. 1.617 and other SARS-CoV-2 variants. Nature 596.7871 (2021): 273-275.
  • Liu, Z. et al., Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization, Cell Host Microbe, 29(3):477-488 (2021).
  • Lu, R. et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395(10224):565-574 (2020).
  • Marze, N. et al., Efficient flexible backbone protein-protein docking for challenging targets, Bioinformatics, 34(20):3461-3469 (2018).
  • Mascola, J.R. and Montefiori, D.C., HIV-1: nature's master of disguise, Nat Med., 9(4):393-4 (2003).
  • Mazzocco, et al., AI aided design of epitope-based vaccine for the induction of cellular immune responses against SARS-CoV-2, Frontiers in Genetics, vol. 12, Mar. 25, 2021.
  • McKeating, J. et al., Characterization of HIV-1 neutralization escape mutants, AIDS, 3(12):777-84 (1989).
  • Meier, J. et al., Language models enable zero-shot prediction of the effects of mutations on protein function, BioRxiv, 30 pages (2021).
  • Mettu, R. et al., Synthetic carbohydrate-based vaccines: challenges and opportunities, J Biomed Sci., 27(1):9, 22 pages (2020).
  • Misener, S. and Krawetz, S., Bioinformatics Methods and Protocols, Methods in Molecular Biology, Humana Press, 132: 478 pages (1999).
  • Moncla, L. et al., Influenza Evolution: New Insights into an Old Foe, Trends Microbiol., 25(6):432-434 (2017).
  • Mouret, Jean-Baptiste and Clune, Jeff, Illuminating search spaces by mapping elites, Université Pierre et Marie Curie-Paris 6, CNRS UMR 7222, France, 15 pages (Preprint—Apr. 21, 2015).
  • Muik, A. et al., Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera, Sci., 371:1152-1153 (2021).
  • Muik, A. et al., Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity, Cell Reports, 42:11288, 13 pages (2023).
  • Muik, A. et al., Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T-cell recognition epitopes, bioRxiv, 19 pages (2022).
  • Myers, E.W., and Miller, W., Optimal alignments in linear space, CABIOS, 4(1):11-17 (1988).
  • Ofer, et al., The language of proteins: NPL, machine learning & protein sequences, Computational and Structural Biotechnology Journal, vol. 19, pp. 1750-1758, Mar. 25, 2021.
  • O'toole, Á. et al., Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool, Virus Evol., 7(2):veab064 (2021).
  • Pierrot, T. et al., Sample Efficient Quality Diversity for Neural Continuous Control, ICLR 2021 Conference Blind Submission, 17 pages (modified May 5, 2023).
  • Quignot, C. et al., InterEvDock3: a combined template-based and free docking server with increased performance through explicit modeling of complex homologs and integration of covariation-based contact maps, Nucleic Acids Res., 49(W1):W277-W284 (2021).
  • Rambaut, A. et al., A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology, Nat Microbiol., 5(11):1403-1407 (2020).
  • Rao, R. et al., Transformer protein language models are unsupervised structure learners, Cold Spring Harbor Laboratory, 37 pages (2020).
  • Rives, A. et al., Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences, Proc Natl Acad Sci USA, 118(15):e2016239118, 12 pages (2021).
  • Sahin, U. et al., BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595.7868 (2021): 572-577.
  • Sahin, U. et al., COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, Nature, 586(7830):594-599 (2020).
  • Salvatori, G. et al., SARS-CoV-2 Spike Protein: an optimal immunological target for vaccines, J Transl Med., 18(1):222, 3 pages (2020).
  • Sevy, A. et al., Integrating linear optimization with structural modeling to increase HIV neutralization breadth, PLoS Comput Biol., 14(2):e1005999, 18 pages (2018).
  • Sevy, A. et al., Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses, Proc Natl Acad Sci USA, 116(5):1597-1602 (2019).
  • Shu, Y. and McCauley, J., Gisaid: Global initiative on sharing all influenza data—from vision to reality, Euro Surveill., 22(13):30494 (2017).
  • Sievers, F. et al., Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega, Mol Syst Biol., 7:539 (2011).
  • Singh, J. et al., SARS-CoV-2 variants of concern are emerging in India, Nat Med., 27(7):1131-1133 (2021).
  • Starr, T. et al., Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, Science, 371(6531):850-854 (2021).
  • Steinegger, M. et al., HH-suite3 for fast remote homology detection and deep protein annotation, BMC Bioinformatics, 20(1):473 (2019).
  • Suryadevara, N. et al., Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein, Cell, 184(9):2316-2331 (2021).
  • Suzek, B. et al., UniRef: comprehensive and non-redundant UniProt reference clusters, Bioinformatics, 23(10):1282-8 (2007).
  • Szoka Jr., F. and Papahadjopoulos, D., Comparative properties and methods of preparation of lipid vesicles (liposomes), Annu Rev Biophys Bioeng., 9:467-508 (1980).
  • Tai, W. et al., Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell Mol Immunol., 17(6):613-620 (2020).
  • Tan, C. et al., A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction, Nat Biotechnol, 38:1073-1078 (2020).
  • Tanaka, S. et al., An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Sci Rep. 11(1):12740 (2021).
  • Tatsis, N. and Hildegund, C., Adenoviruses as vaccine vectors, Mol Ther., 10(4):616-29 (2004).
  • Traggiai, E. et al., An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus, Nat Med., 10(8):871-5 (2004).
  • Twohig, K. et al., Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study, Lancet Infect Dis., 22(1):35-42 (2022).
  • Vaswani, A. et al., Attention Is All You Need, arXiv, 15 pages (Aug. 2, 2023).
  • Wadhwa, A. et al., Opportunities and Challenges in the Delivery of mRNA-based Vaccines, Pharmaceutics, 12(2):102 (2020).
  • Walls, A. et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181(2):281-292 (2020).
  • Wang, Z. et al., mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants, Nature, 592(7855):616-622 (2021).
  • Wei, X. et al., Antibody neutralization and escape by HIV-1, Nature, 422(6929):307-12 (2003).
  • Weigang, S. et al., Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants, Nat Commun., 12(1):6405 (2021).
  • Weisblum, Y. et al., Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants, Elife, 9:e61312 (2020).
  • Wu, F. et al., Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China, bioRxiv, Cold Spring Harbor Laboratory, 32 pages (2020).
  • Yan, R. et al., Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies, Cell Res., 31(5):517-525 (2021).
  • Zepp, Fred, Principles of vaccine design-Lessons from nature, Vaccine, 28 Suppl 3:C14-24 (2010).
  • Zhang, L. et al., Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation, Proc Natl Acad Sci USA, 118(47):e2109905118 (2021).
  • Coronavirus Update: These COVID 19 Map Dashboards Track the Spread Mar. 23, 2020, Solutions Review, site visited Jan. 13, 2026: https:l/solutionsrevi ew.com/business-intelligence/coronavirus-update-these-covid-19-map-dashboards-track-the-spread/ (Year: 2020).
  • Global Infectious Diseases in January 2023_ Monthly Analysis Feb. 18, 2023, Science Open, site visited Jan. 13, 2026: https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2023-1001 (Year: 2023).
  • Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases Oct. 9, 2022, Airfinity, site visited Jan. 13, 2026: https://www.airfinity.com/articles/introducing-airfinity-biorisk-infectious-disease-risk-surveillance-analysis (Year: 2022).
  • National Library of Medicine (National Center for Biotechnology Information), https://www.ncbi.nlm.nih.gov/, accessed on Jul. 19, 2024).
  • Power BI Tutorial for Beginners 8—Pie Chart and Map in Power BI Sep. 21, 2020, Youtube, site visited Jan. 13, 2026: https://www.youtube.com/watch?v=GcbGa7BtAhU (Year: 2020).
Patent History
Patent number: D1154704
Type: Grant
Filed: Feb 7, 2024
Date of Patent: Oct 20, 2026
Assignees: BioNTech SE (Mainz), InstaDeep Ltd (London)
Inventors: Alexander Muik (Seeheim-Jugenheim), Yunguan Fu (London), Alexandra Walls (Cambridge, MA), Rafal Okuniewski (London), Asaf Poran (Stoneham, MA), Nicolas Winfried Pfeuffer (Frankfurt am Main)
Primary Examiner: Catherine S Posthauer
Assistant Examiner: Ava Etemadi
Application Number: 29/928,071
Classifications
Current U.S. Class: Generated Image (D14/485)